Henrik Blou, Gubra CEO
April 1, 2025 10:39 AM EDT
R&D

Gubra’s Ab­b­Vie-part­nered amylin looks com­pet­i­tive with Zealand’s in ear­ly tri­al

Elizabeth Cairns

Senior biopharma journalist

GUBamy, the amylin obe­si­ty can­di­date de­vel­oped by Gubra and li­censed to Ab­b­Vie for $350 mil­lion last month, demon­strat­ed en­cour­ag­ing weight loss in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times